The Causes and Treatment of the Anaemia of Prematurity

2015 ◽  
pp. 291-295
Author(s):  
W. Waronski ◽  
M. Piasecka ◽  
I. Norska ◽  
A. Lukas
Keyword(s):  
Anaemia Of Prematurity

scholarly journals Erythropoietin responsive progenitors in anaemia of prematurity.

1991 ◽  
Vol 66 (7 Spec No) ◽  
pp. 810-811 ◽  
Author(s):  
A J Emmerson ◽  
N B Westwood ◽  
R A Rackham ◽  
C M Stern ◽  
T C Pearson
Keyword(s):  
Anaemia Of Prematurity

Physiological Anaemia of Infancy and the Anaemia of Prematurity

1978 ◽  
Vol 7 (1) ◽  
pp. 3-18
Author(s):  
James A. Stockman ◽  
Frank A. Oski
Keyword(s):  
Anaemia Of Prematurity

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

2013 ◽  
Vol 38 (3) ◽  
pp. 119-123 ◽  
Author(s):  
BHN Yasmeen ◽  
MAKA Chowdhury ◽  
MM Hoque ◽  
MM Hossain ◽  
R Jahan ◽  
...  
Keyword(s):  
Folic Acid ◽  
Birth Weight ◽  
Low Birth Weight ◽  
Recombinant Human Erythropoietin ◽  
Very Low Birth Weight ◽  
Controlled Trial ◽  
Control Group ◽  
Short Term ◽  
Human Erythropoietin ◽  
Anaemia Of Prematurity

Premature infants especially those with birth weight <1500 g suffer from Anaemia of prematurity (AOP) and associated problems. Erythropoietin therapy is a safe effective way to prevent and to treat anaemia of prematurity. To evaluate the effect of short term administration of recombinant human erythropoietin (rHuEPO) with iron and folic acid in very low birth weight (VLBW) neonates in the prevention of anaemia of prematurity. A randomized controlled trial was carried out at Dhaka Shishu Hospital. Sixty preterm very low birth weight (PTVLBW) babies were enrolled in this study. Thirty were assigned to rHuEPO group and 30 as control. Baseline haematologic values were estimated before administration of rHuEPO. From day 7 of life rHuEPO-200 IU/kg/dose subcutaneously every alternate day for 2 weeks was administered to rHuEPO group. All infants in both groups have received oral iron, folic acid from day 14. Clinical and haematological assessment was done at 6 and 10 weeks of life. Baseline clinical characteristics and haematologic values were almost similar in both groups. This study has shown increase in haematological values(haemoglobin and haematocrit) and reduction in the number of blood transfusions during both the 1st and 2nd follow up in rHuEPO group in comparison to control group (p<0.01). Short term rHuEPO appears to be very effective in prevention of Anaemia of prematurity. DOI: http://dx.doi.org/10.3329/bmrcb.v38i3.14340 Bangladesh Med Res Counc Bull 2012; 38(3): 119-123 (December)

Circulating stem cell factor in anaemia of prematurity

1996 ◽  
Vol 45 (1-2) ◽  
pp. 161-162
Author(s):  
R.J. Thwaites ◽  
N.B. Westwood ◽  
T.C. Pearson ◽  
A.D. Milner
Keyword(s):  
Stem Cell ◽  
Stem Cell Factor ◽  
Anaemia Of Prematurity

scholarly journals The Prevention of Anaemia of Prematurity

1962 ◽  
Vol 37 (193) ◽  
pp. 297-299 ◽  
Author(s):  
W. D. Elliott
Keyword(s):  
Anaemia Of Prematurity

Effects of Recombinant Human Erythropoietin in Infants with Very Low Birth Weights

1996 ◽  
Vol 24 (2) ◽  
pp. 190-198 ◽  
Author(s):  
N Samanci ◽  
F Ovali ◽  
T Da͂o͂lu
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Day Treatment ◽  
Haemoglobin Concentration ◽  
The Third ◽  
Human Erythropoietin ◽  
Erythropoietin Production ◽  
End Of Treatment ◽  
Anaemia Of Prematurity ◽  
Oral Supplements ◽  
To Receive

Anaemia of prematurity, a postnatal fall in haemoglobin concentration and haematocrit, is particularly common in those born at less than 32 weeks of gestation. Experimental and clinical data implicate inadequate erythropoietin production as an important reason. In this study recombinant human erythropoietin (r-HuEpo) was used in an attempt to treat or prevent this anaemia and thereby provide an alternative to erythrocyte transfusions. Premature infants (birth weight ≤ 1250 g and gestational age ≤ 32 weeks), who were likely to need transfusions, were randomly assigned to receive 4 weeks of treatment with either subcutaneously administered r-HuEpo (200 U; n = 12) or placebo ( n = 12), three times weekly. All patients had oral supplements of elemental iron at a dose of 3 mg/kg/day. Treatment was started in the third week of life. Reticulocyte counts were significantly raised ( P < 0.05) in the group treated with r-HuEpo at the end of treatment. The neonates in the group treated with r-HuEpo needed fewer erythrocyte transfusions than those in the placebo group during treatment. There were no toxic effects attributable to r-HuEpo. The results indicate that treatment of infants with very low birth weights with r-HuEpo will reduce their need for erythrocyte transfusions

PP-73. Algorithm for treatment of anaemia of prematurity with r-hu-erythropoietin

2010 ◽  
Vol 86 ◽  
pp. S47
Author(s):  
Tania Pramatarova ◽  
Nina Yarakova ◽  
Boriana Sluncheva ◽  
Petia Radulova ◽  
Sani Hitrova ◽  
...  
Keyword(s):  
Anaemia Of Prematurity
Sign in / Sign up

Export Citation Format

Share Document